Nihal Sinha is a Partner at F-Prime Capital based in the London office and focuses primarily on biotech and healthcare IT in Europe. At F-Prime, Nihal serves on the board of directors of several companies he helped create and finance including CHARM Therapeutics and Aviado Bio. Nihal was part of the founding team of the cell and gene therapy company Orchard Therapeutics, and currently serves on the board of directors at Ensoma, RIGImmune and T-Therapeutics. Prior to joining F-Prime in 2013, he worked as a strategy consultant at BCG and as an academic physician at Oxford University and UCL Hospitals. Nihal holds a MB BChir with distinction from the University of Cambridge and is a Member of the Royal College of Physicians.